FDA Orange Book · active-ingredient family
Clevidipine
Clevidipine is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:CLEVIPREX · NDA 022156
1
Brand (NDA)
0
Generics (ANDA)
3
Listed patents
0
Exclusivity periods
Brand (NDA) products · emulsion
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CLEVIPREXRLD×3 | CHIESI | NDA 022156 | — | Aug 01, 2008 |
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8658676 | Oct 10, 2031 | in 5 yr 5 mo | Product |
| 10010537 | Oct 10, 2031 | in 5 yr 5 mo | Product |
| 11103490 | Oct 10, 2031 | in 5 yr 5 mo | Product |
Clevidipine — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
